Pfanstiehl
United States 106 employees Updated 9 July 2026
Pfanstiehl is an API manufacturer based in United States. It holds 6 active US drug master files across a filed portfolio of 6 molecules. Its most recent recorded inspection, by US FDA, closed on 23 January 2023 as NAI.
1
registered plants
1 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
7 of 7 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 23 January 2023 NAI US FDA
- 5 October 2017 NAI US FDA
- 9 February 2016 NAI US FDA
- 19 June 2013 NAI US FDA
- 11 February 2013 VAI US FDA
- 17 August 2010 NAI US FDA
- 8 May 2009 NAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Waukegan, United States | 1410747 |
What they file, and where
| Molecule | Regulators | Docs |
| Ammonium Lactate | US FDA | 1 |
| Mannose | US FDA | 1 |
| Methotrexate | US FDA | 1 |
| Podofilox | US FDA | 1 |
| Streptozocin | US FDA | 1 |
| Tromethamine | US FDA | 1 |
Also appears on these molecule pages
Comparing suppliers?
Choose your molecules and target markets. Pfanstiehl comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- 2 active litigation matters are on record.
- The most recent inspection outcome was NAI, on 23 January 2023.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability